Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
13/08/2026 12:27
BRIEF-Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026 Aug 13 (Reuters) - Sagimet Biosciences Inc. SGMT.O:
SAGIMET BIOSCIENCES RECEIVES FDA “STUDY MAY PROCEED” LETTER AND IND CLEARANCE FOR PHASE 3 TRIAL IN ACNE IN ADOLESCENT AND ADULT PATIENTS
SAGIMET BIOSCIENCES INC.: PHASE 3 CLINICAL TRIAL IS ON TRACK TO INITIATE IN SECOND HALF OF 2026
SAGIMET BIOSCIENCES - PHASE 3 TRIAL ON TRACK TO INITIATE IN SECOND HALF OF 2026
Source text: ID:nGNX43W8nr
Further company coverage: SGMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage